Overview
Launching orphan medicines excellently will become even more important over the next five years as more patients with rare diseases have pharmacotherapies available.
The UK has some of the best patient data available anywhere in the world, and a preeminent position in the collection of cancer data at both an individual tumour and patient level.
Drug development can be quite a risky business at the best of times, but particularly in the biotech sector where companies may only have a few assets to their name.
Pharma giant UCB is to invest around £1 billion in the UK as part of a second life sciences sector deal with the UK government, with industry names such as Roche and IQVIA also committing t
